NKTX - Nkarta, Inc.
IEX Last Trade
2.405
-0.010 -0.416%
Share volume: 9,613
Last Updated: Fri 27 Dec 2024 08:30:13 PM CET
Research and Development in Biotechnology (except Nanobiotechnology):
0.25%
PREVIOUS CLOSE
CHG
CHG%
$2.42
-0.01
-0.41%
Fundamental analysis
4%
Profitability
0%
Dept financing
0%
Liquidity
0%
Performance
10%
Performance
5 Days
-3.20%
1 Month
-19.06%
3 Months
-46.46%
6 Months
-58.70%
1 Year
-54.93%
2 Year
-52.92%
Key data
Stock price
$2.40
DAY RANGE
$2.37 - $2.45
52 WEEK RANGE
$2.23 - $16.24
52 WEEK CHANGE
-$63.33
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
11/07/2024
Company detail
CEO: Paul J. Hastings
Region: US
Website: nkartatx.com
Employees: 140
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in Biotechnology (except Nanobiotechnology)
Sector: Professional, Scientific, and Technical Services
Region: US
Website: nkartatx.com
Employees: 140
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in Biotechnology (except Nanobiotechnology)
Sector: Professional, Scientific, and Technical Services
Nkarta, Inc., a a clinical-stage biopharmaceutical company, develops and commercializes cell therapies for cancer treatment. The company's approach for cellular immunotherapy involves chimeric antigen receptors on the surface of a natural killer (NK) cell that enable the cell to recognize specific proteins or antigens.
Recent news